home / stock / ixhl / ixhl news

IXHL News and Press, Incannex Healthcare Limited From 06/16/23

Stock Information
Company Name: Incannex Healthcare Limited
Stock Symbol: IXHL
Market: NASDAQ
Website: incannex.com.au
Menu
IXHL IXHL Quote IXHL Short IXHL News IXHL Articles IXHL Message Board
Get IXHL Alerts

News, Short Squeeze, Breakout and More Instantly...
IXHL - Incannex Appoints Principal Investigators for IHL-42X Phase 2/3 Clinical Trial

MELBOURNE, Australia, June 16, 2023 (GLOBE NEWSWIRE) -- Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), (‘Incannex’ or the ‘Company’) a clinical-stage pharmaceutical company developing unique medicinal cannabinoid pharmaceutical products and psychedelic medicine...
IXHL - World Renowned International Psychedelics Experts Join Clarion Clinics Advisory Board

Highlights: Three world-leading clinical psychedelics experts join Clarion Clinics Advisory Board. Dr. Bill Richards is among the world’s best known psychedelic researchers and practitioners. He has had a multi-decade career at the forefront of psychedelic research, thera...

IXHL - Incannex Company Presentation - Presentation of Psychennex, Psychedelic Therapies Subsidiary Company

MELBOURNE, Australia, May 16, 2023 (GLOBE NEWSWIRE) -- Incannex Healthcare Ltd (Nasdaq: IXHL) (ASX: IHL) (‘Incannex’ or ‘the Company’) is pleased to announce a company presentation which details activities of its psychedelic therapies subsidiary company, called Psychen...

IXHL - Incannex enters a lease for first psychedelic-assisted psychotherapy clinic

MELBOURNE, Australia, May 05, 2023 (GLOBE NEWSWIRE) -- Incannex Healthcare Ltd (Nasdaq: IXHL) (ASX: IHL) (‘Incannex’ or ‘the Company’), a medicinal cannabinoid and psychedelic pharmaceutical development company, is delighted to announce that its subsidiary company, Cla...
IXHL - Incannex Company Presentation - Results from Phase 1 Clinical Trial to Assess Proprietary IHL-675A

MELBOURNE, Australia, May 03, 2023 (GLOBE NEWSWIRE) -- Incannex Healthcare Ltd (Nasdaq: IXHL) (ASX: IHL) (‘Incannex’ or ‘the Company’) is pleased to announce a company presentation containing data and analysis of the results from the Phase 1 clinical trial undertaken t...

IXHL - Incannex Announces Final Results from Phase 1 Clinical Trial Assessing Safety and Pharmacokinetics of IHL-675A

MELBOURNE, Australia, May 02, 2023 (GLOBE NEWSWIRE) -- Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), (‘Incannex’ or the ‘Company’) a clinical-stage pharmaceutical company developing unique medicinal cannabinoid pharmaceutical products and psychedelic medicine ...

IXHL - Incannex Appoints QPS to Advance CannQuit-N(TM) (Nicotine), CannQuit-O(TM) (Opioid) and Renecann(TM) Products in the USA and EU

MELBOURNE, Australia, April 14, 2023 (GLOBE NEWSWIRE) -- Incannex Healthcare Ltd (Nasdaq: IXHL) (ASX: IHL) (‘Incannex’ or ‘the Company’) a pharmaceutical company developing proprietary medicinal cannabinoid products and psychedelic assisted psychotherapies for unmet me...
IXHL - Incannex to Commercialise its Psychedelic Clinics Business in Collaborative Partnership with Leading Psychedelic Experts

Highlights: Incannex plans to open multiple psychedelic-assisted psychotherapy clinics in Australia and overseas. First clinic will open in Melbourne in 2023, followed by rapid expansion based on development of sound operating model. Dr. Paul Liknaitzky, Professor Suresh Sundram...

IXHL - Interim review of proprietary PsiGAD clinical trial data indicates no safety concerns and projects a statistically significant benefit for the psilocybin arm versus the placebo arm in those participants who have completed the treatment

Highlights: Interim analysis of study data to date indicates that there is a greater than 85% chance (>85%, alpha error probability 0.05) of the study showing a statistically significant benefit for the psilocybin treatment arm versus the placebo treatment arm at the conclusion of th...

IXHL - Incannex Engages Catalent for Development and cGMP Manufacture of Psilocybin Drug Product for Clinical Trials and Potential Commercial Use

Highlights: Incannex has engaged Catalent for the development and cGMP manufacture of Incannex’s own psilocybin drug product. The psilocybin is designed for use in Incannex’s ongoing psilocybin-assisted psychotherapy “PsiGAD” clinical development program ...
Previous 10 Next 10